Posts Tagged ‘Pear Therapeutics’
Beyond the clinic: Can digital therapeutics (DTx) help boost mental health in the workforce at scale?
Hoping to Avoid Pear’s Fate, Behavioral Health-Focused DTx Companies Look to Employer Market (Behavioral Health Business): The digital therapeutics (DTx) industry is at a crossroads after one of the most prominent companies in the space, Pear Therapeutics, filed for bankruptcy earlier this year. The turmoil comes after DTx began catching on in the behavioral health…
Read MoreOn the 7 Habits of Highly Stress-Resilient Minds, cognitive screenings, anti-amyloid drugs, and more
Welcome to a new edition of SharpBrains e‑newsletter, this time covering the latest developments in stress research, meditation, virtual reality, anti-amyloid drugs, cognitive screenings, and more. #1. The 7 Habits of Highly Stress-Resilient Minds “Anything worth doing will have aspects of stress woven through: challenge, discomfort, risk. We can’t change that. But what we can change is…
Read MorePear Therapeutics loses 97% of its market capitalization since 2021, explores strategic alternatives
Pear Therapeutics exploring sale, other ‘strategic alternatives’ (MobiHealth News): Prescription digital therapeutics company Pear Therapeutics is exploring “strategic alternatives,” including a possible company sale, merger or acquisition. In a press release, the company said it hired a financial advisor to look into actions that could “maximize shareholder value.” That includes a potential sale, M&A, divestiture…
Read MoreDebate: Will digital therapeutics gain the required levels of awareness, adoption, reimbursement and fulfillment to become sustainable?
Can digital therapeutics become profitable? (MedTechDive): In 2020, the Food and Drug Administration cleared Akili Interactive’s video game to improve attention in kids with ADHD. It was the first time that a video game for treatment was cleared by the agency, and is one example of a digital therapeutic, a class of software-based treatments with…
Read MoreUpdate: Why MDMA-assisted psychotherapy may become an FDA-approved treatment for PTSD within 2 years
Welcome to a new edition of SharpBrains’ e‑newsletter, sharing important brain/ mental health news plus a few fun optical illusions to tease and appreciate our unique human minds. #1. Why MDMA-assisted psychotherapy may become an FDA-approved treatment for PTSD within 2 years “We are a pharmacist and physician team who investigate the benefits and harms associated with…
Read MorePear Therapeutics raises $175M and goes public via SPAC deal raising the profile of prescription digital therapeutics
Digital health firm Pear goes public, raising $175 million (pharmaforum): Pear will make its debut on the exchange today after combining with Thimble Point – a special purpose acquisition company (SPAC) – in a deal that sidestepped the conventional initial public offering (IPO) route and has propelled its valuation to around $1.6 billion … Pear specialises…
Read More